US009616024B2

(12) United States Patent

Zeng et al.

(10) Patent No.: US 9,616,024 B2
(45) Date of Patent: Apr. 11, 2017

(54) **PROCESS FOR PREPARING A MEDICAMENT**

(71) Applicant: **Norton Healthcare Ltd.**, London (GB)

(72) Inventors: **Xian-Ming Zeng**, London (GB); **Seah Kee Tee**, London (GB)

(73) Assignee: **Norton Healthcare Ltd.**, London (GB)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/137,671**

(22) Filed: **Apr. 25, 2016**

(65) **Prior Publication Data**

US 2016/0235678 A1 Aug. 18, 2016

Related U.S. Application Data

(62) Division of application No. 10/594,473, filed as application No. PCT/US2004/028345 on Sep. 1, 2004, now Pat. No. 9,345,664.

(60) Provisional application No. 60/499,582, filed on Sep. 2, 2003.

(51) **Int. Cl.**

A61K 9/14	(2006.01)
A61M 15/00	(2006.01)
A61K 31/58	(2006.01)
A61K 9/00	(2006.01)
A61K 31/167	(2006.01)
A61K 31/137	(2006.01)
A61K 9/16	(2006.01)
A61K 31/56	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 9/1694*** (2013.01); ***A61K 9/0075*** (2013.01); ***A61K 9/1623*** (2013.01); ***A61K 31/137*** (2013.01); ***A61K 31/167*** (2013.01); ***A61K 31/56*** (2013.01); ***A61K 31/58*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,957,965	A	5/1976	Hartley
4,161,516	A	7/1979	Bell
5,518,998	A	5/1996	Backstrom
6,030,604	A	2/2000	Trofast
6,045,828	A	4/2000	Bystrom
6,116,237	A	9/2000	Schultz
6,371,171	B1	4/2002	Trofast
2002/0106332	A1	8/2002	Walz
2002/0122826	A1	9/2002	Lizio
2003/0068278	A1	4/2003	Boeck
2004/0258626	A1	12/2004	Zeng
2005/0158248	A1	7/2005	Zeng
2006/0292083	A1	12/2006	Zeng

FOREIGN PATENT DOCUMENTS

GB	1569611	6/1980
WO	9210229	6/1992
WO	9500128	1/1995
WO	03024396	3/2003
WO	2004017918	3/2004

OTHER PUBLICATIONS

Written Submission in Preparation to Oral Proceeding filed on Dec. 3, 2012, by AstraZeneca AB., 5 pages.

Written Submission in Preparation to Oral Proceeding filed on Dec. 10, 2012, by Vectura Ltd., 6 pages.

Finlay, "The Mechanics of Inhaled Pharmaceutical Aerosols," 2001, p. 149.

Patentee's observations statement dated Jun. 25, 2012 (opposition by AstraZeneca AB and Vectura Ltd to European Patent No. 1 699 434), 16 pages.

De Villiers, M.M., "Description of the Kinetic of the Deagglomeration of Drug Particle Agglomerates During Powder Mixing," International Journal of Pharmaceutics, (1997) vol. 151, pp. 1-6.

Keating, G.M., et al., "Airmax™ 1 a Multi-Does Dry Powder Inhaler," Adis New Device Profile, (2002), vol. 62, No. 13, pp. 1887-1895.

Zeng, X.M. et al., "The Influence of Lactose Carrier on the Content Homogeneity and Dispersibility of Beclomethasone Dipropionate from Dry Powder Aerosols," International Journal of Pharmaceutics, (2000), vol. 197, pp. 41-52.

Supplemental European Search Report EP 04 78 2768 dated Mar. 18, 2009, 2 pages.

Begat et al., "The Role of Force Control Agents in High-Dose Dry Powder Inhaler Formulations," Journal of Pharmaceutical Sciences, vol. 98, No. 8, Aug. 2009, pp. 2770-2783.

Ikegami et al., "Simultaneous particulate design of primary agglomerated crystals of steroid by spherical agglomeration in liquid for dry powder inhalation," Powder Technology, 2003, vol. 130, pp. 290-297.

Ikegami et al., "In vitro inhalation behavior of spherically agglomerated steroid particles with carrier lactose," Advanced Powder Technol., 2000, vol. 11, No. 3, pp. 323-332.

(Continued)

Primary Examiner — Robert A Wax

Assistant Examiner — Randeep Singh

(74) *Attorney, Agent, or Firm* — Morgan, Lewis & Bockius, LLP

(57) **ABSTRACT**

The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.

9 Claims, 5 Drawing Sheets